You are here:


[2] European Union (2003) European Union Directive 2002/98/EC setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC.
[4] Faber JC. Worldwide overview of existing haemovigilance systems. Transfusion and Apheresis Science 2004; 31:99‑110.
[5] World Health Organization (WHO) (2011). Global Database on Blood Safety Summary Report 2011.
[6] Calman K. The Health of the Nation. British Journal of Hospital Medicine 1996; 56 pp125-126.
[7] Australian Red Cross Blood Service (the Blood Service) (2012). Blood Component Information Circular of Information An extension of blood component labels 2012.
[8] Geiger TL, Howard SC. Acetaminophen and diphenhydramine pre-medication for allergic and febrile non haemolytic transfusion reactions: good prophylaxis or bad practice? Transfusion Medicine Review 2007; 21(1):1-12.
[9] Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion 2007; 47(6):1089-1096.
[10] Australian and New Zealand Society of Blood Transfusion Ltd & Royal College of Nursing Australia (ANZSBT&RCNA) (2012). Guidelines for the administration of blood products. 2nd Edition.
[11] The Blood Service. Febrile non-haemolytic transfusion reactions (FNHTR). Australia.
[12] Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT. Pre-storage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 2001; 41 pp997-1000.
[13] The Blood Service. Minor allergic reactions (urticaria). Australia.
[14] Tinegate H, Birchall J, Gray A, Haggas R, Massey E, Norfolk D, Pinchon D, Sewell C, Wells A, Allard S. Guideline on the investigation and management of acute transfusion reactions. British Journal of Haematology 2012; 159(2):143-153.
[15] Rüggeberg JU, Gold MS, Bayas J-M, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25(31):5675-5684.
[16] Johansson SG, Hourihnne JO , Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56(9):813-824.
[17] Johansson SG. Bieber T, Dahl R, Friedmann PS. Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy and Clinical Immunology 2004; 113(5):832-836.
[18] Sampson HA, Munoz-Furlong A, Bock SA , Schmitt C, Buss R, Chowdhury BA, et al. Symposium on the definition and management of anaphylaxis: summary report. Journal of Allergy and Clinical Immunology 2005; 115(3):584-591.
[19] The Blood Service. Severe allergic reactions (anaphylactoid reactions or anaphylaxis). Australia.
[20] The Blood Service. Acute haemolytic transfusion reaction. Australia.
[21] Stainsby D, Knowles SM, Milkins C, Jones H, Cohen H. Can haemolytic transfusion reactions be avoided by better transfusion practice? Vox Sanguinis 2005; 89 (Suppl. 1):14.
[22] Milkins C, Knowles S, DeSilva M, Contreras M, Stainsby D. Prevention and diagnosis of delayed haemolytic transfusion reactions. Vox Sanguinis 2006; 91(4):365-367.
[23] Serious Hazards of Transfusion (SHOT). Annual SHOT Report 2011. SHOT, National Blood Service, National Health Service, United Kingdom.
[24] Hannema SE, Brand A, van Meurs A, Smiers F J. Delayed hemolytic transfusion reaction with hyperhemolysis after first red blood cell transfusion in child with β-thalassemia: challenges in treatment. Transfusion 2010; 50(2): 429-432.
[25] The Blood Service. Delayed haemolytic transfusion reactions (DHTR). Australia.
[26] Zhou L, Giacherio D, Cooling L, et al. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion 2005; 45(7): 1056-1063.
[27] Popovsky MA. Transfusion-associated circulatory overload. ISBT Science Series 2008; 3(1) pp166-169.
[28] The Blood Service. Transfusion-related circulatory overload (TACO). Australia.
[29] S Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol. 2013 Nov;163(3):303-14. doi: 10.1111/bjh.12547. Epub 2013 Sep 14.
[30] New Zealand Blood Service. National Haemovigilance Programme Annual Report 2012. New Zealand.
[31] The Blood Service. Transfusion-related Acute Lung Injury (TRALI). Australia.
[32] The Blood Service. Transfusion associated sepsis. Australia.
[33] Australian Commission on Safety and Quality in Health Care (2012). Standard 7: Blood and blood products - safety and quality improvement guide. New South Wales.
[34] Blood Matters (2003) Serious transfusion incident report 2009–11. Department of Health, Victoria.
[35] Eder AF, Dy BA, Kennedy JM, Notari IV EP, Strupp A, Wissel ME, Reddy R, Gibble J, Haimowitz MD, Newman BH, Chambers LA, Hillyer CD, Benjamin RJ. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008; 48: 1809-1819. doi: 10.1111/j.1537-2995.2008.01811.x.
[36] Newman, Bruce H, Pichette S, Pichette D, Dzaka E. Adverse effects in blood donors after whole-blood donation: a study of 1000 blood donors interviewed 3 weeks after whole-blood donation. Transfusion 2003; 43: 598-603. doi: 10.1046/j.1537-2995.2003.00368.x.
[37] Goldman M, Osmond L, Yi Q-L, Cameron-Choi K, O'Brien SF. Frequency and risk factors for donor reactions in an anonymous blood donor survey. Transfusion 2012: doi: 10.1111/trf.12011.
[38] Eder AF. Improving Safety for Young Blood Donors. Transfusion Medicine Reviews 2012:26 (1): 14-26.
[40] Therapeutic Goods Administration. Reporting medicine and vaccine adverse events.
[41] NBA. Australian Bleeding Disorders Registry (ABDR). Canberra.
[42] NBA. IVIg criteria for use. Canberra.
[43] Australian Bureau of Statistics (ABS). Australian Demographic Statistics. Cat. no. 3101.0. Canberra.
[44] ABS (2013). Australian Demographic Statistics, June 2013. ABS-3101.0. Canberra.
[45] Department of Health (2010). Australia to 2050: future challenges. Canberra.
[46] OECD (2014). Life expectancy (indicator). doi: 10.1787/27e0fc9d-en.
[47] Australian Institute of Health and Welfare (AIHW). Limitations of the data. Canberra.
[48] Cobain TJ, Vamvakis EC, Wells A, Titlestad K. A Survey of the Demographics of Blood Use. Transfusion Medicine 2007; 17(1):1-15.
[49] SA Health and the Blood Service. Red cell use in South Australia 2007–2009: trends, patterns and a focus on haematology. South Australia.
[50] Shortt J, Polizzotto MN, Waters N, Borosak M, Moran M, Comande M, et al. Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use. Transfusion 2009; 49(11):2296 - 2303.
[51] Tinegate H, Chattree S, Iqbal A, Plews D, Whitehead J, Wallis JP. Ten-year pattern of red blood cell use in the North of England. Transfusion 2013, 53(3): 483-489.
[52] National Blood Authority (NBA) (2014). National Blood Authority Annual Report 2013–14. Canberra.
[53] ABS (2014). Australian demographic statistics, March 2014. Cat. no. 3101.0. Canberra.
[54] Noel L, Debeir J, Cosson A. The French haemovigilance system. Vox Sanguinis 1998; 74(S2):441-445.
[56] de Vries RR, Faber JC, Strengers PF. Haemovigilance: an effective tool for improving transfusion practice. Vox Sanguinis 2011; 100(1):60-67.
[57] International Haemovigilance Network (IHN). International Haemovigilance Seminar.
[59] World Health Organization (WHO). Global Database on Blood Safety Summary Report 2011.
[61] SHOT. Annual SHOT Report 2013. The United Kingdom.
[62] Transfusion Reactions in Patients (TRIP). TRIP Annual report 2012: haemovigilance. Extended version. TRIP Haemovigilance and Biovigilance Office, The Netherlands.
[65] Food and Drug Administration (2014). Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2013. The United States.
[66] Public Health Agency of Canada. Summary Results for 2006-2012. Canada.